These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 29370102)

  • 1. NMR-Fragment Based Virtual Screening: A Brief Overview.
    Singh M; Tam B; Akabayov B
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29370102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical aspects of NMR-based fragment screening.
    Lepre CA
    Methods Enzymol; 2011; 493():219-39. PubMed ID: 21371593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective progression of nuclear magnetic resonance-detected fragment hits.
    Eaton HL; Wyss DF
    Methods Enzymol; 2011; 493():447-68. PubMed ID: 21371601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of Solution NMR in Drug Discovery.
    Shi L; Zhang N
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33499337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Process of Fragment-Based Lead Discovery-A Perspective from NMR.
    Ma R; Wang P; Wu J; Ruan K
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
    Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
    Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NMR quality control of fragment libraries for screening.
    Sreeramulu S; Richter C; Kuehn T; Azzaoui K; Blommers MJJ; Del Conte R; Fragai M; Trieloff N; Schmieder P; Nazaré M; Specker E; Ivanov V; Oschkinat H; Banci L; Schwalbe H
    J Biomol NMR; 2020 Nov; 74(10-11):555-563. PubMed ID: 32533387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hit-to-Lead: Hit Validation and Assessment.
    Hevener KE; Pesavento R; Ren J; Lee H; Ratia K; Johnson ME
    Methods Enzymol; 2018; 610():265-309. PubMed ID: 30390802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMR screening and hit validation in fragment based drug discovery.
    Campos-Olivas R
    Curr Top Med Chem; 2011; 11(1):43-67. PubMed ID: 20809889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment Screening by NMR.
    Davis BJ
    Methods Mol Biol; 2021; 2263():247-270. PubMed ID: 33877602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMR spectroscopy: the swiss army knife of drug discovery.
    Horst R; Farley KA; Kormos BL; Withka JM
    J Biomol NMR; 2020 Nov; 74(10-11):509-519. PubMed ID: 32617727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMR screening in fragment-based drug design: a practical guide.
    Kim HY; Wyss DF
    Methods Mol Biol; 2015; 1263():197-208. PubMed ID: 25618347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisiting biomolecular NMR spectroscopy for promoting small-molecule drug discovery.
    Hanzawa H; Shimada T; Takahashi M; Takahashi H
    J Biomol NMR; 2020 Nov; 74(10-11):501-508. PubMed ID: 32306215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virtual screen to NMR (VS2NMR): Discovery of fragment hits for the CBP bromodomain.
    Spiliotopoulos D; Zhu J; Wamhoff EC; Deerain N; Marchand JR; Aretz J; Rademacher C; Caflisch A
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2472-2478. PubMed ID: 28410781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists.
    Wu B; Barile E; De SK; Wei J; Purves A; Pellecchia M
    Curr Top Med Chem; 2015; 15(20):2032-42. PubMed ID: 25986689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragments: where are we now?
    Osborne J; Panova S; Rapti M; Urushima T; Jhoti H
    Biochem Soc Trans; 2020 Feb; 48(1):271-280. PubMed ID: 31985743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [NMR screening in fragment-based drug discovery].
    Hanzawa H; Takizawa T
    Yakugaku Zasshi; 2010 Mar; 130(3):325-33. PubMed ID: 20190517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contributions of computational chemistry and biophysical techniques to fragment-based drug discovery.
    Gozalbes R; Carbajo RJ; Pineda-Lucena A
    Curr Med Chem; 2010; 17(17):1769-94. PubMed ID: 20345344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.